Lumida
/REGN
⌘K
Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

REGN
$781.49USD-1.48%-11.77 today

MARKET CAP

80.5B

P/E (TTM)

16.9x

FWD P/E

12.8x

DAY RANGE

$781 – $800

52W RANGE

$541
$859

AI Summary

Stalk
StalkMedium

REGN is in a modest pullback within its longer-term uptrend. Short-term technicals show price under declining 9/20 EMAs and RSI drifting lower, suggesting room for mean-reversion toward the rising 50-day SMA around the 751 area. The medium-term stage 2 uptrend remains intact, so buying on a pullback into the 780–750 support zone is preferred. Execution should be deferred (stalk) for confirmation of support and improving momentum near the 50-day SMA before initiating new exposure.

  • Q2 revenue $4.3B (+17% YoY) and Dupixent sales $6B (+38% YoY)
  • Pipeline of ~50 active trials, with oncology and genetic therapies advancing
  • Dupixent dependency creates revenue risk if growth slows
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$16.1B$12.2B$13.1B$14.2B$14.3B
YoY %+89.1%-24.3%+7.8%+8.3%+1.0%
P / Sales4.4x6.7x7.8x5.8x5.8x
EV / Sales4.6x7.0x8.2x6.2x6.3x
Gross Profit, Adj.$13.6B$10.6B$11.3B$12.2B$12.2B
YoY %+84.8%-22.2%+6.5%+8.2%+0.1%
Margin %84.8%87.2%86.2%86.1%85.4%
EV / Gross Profit5.5x8.0x9.5x7.2x7.4x
EBITDA, Adj.$9.2B$5.1B$4.5B$4.5B$4.1B
YoY %+142.2%-45.0%-12.1%+1.4%-9.2%
Margin %57.4%41.7%34.0%31.9%28.7%
EV / EBITDA8.1x16.8x24.0x19.4x21.9x
EBIT$8.9B$4.7B$4.0B$4.0B$3.6B
YoY %+150.1%-47.0%-14.6%-0.0%-11.8%
Margin %55.7%38.9%30.8%28.5%24.9%
EV / EBIT8.3x18.0x26.5x21.7x25.2x
Net Income$8.1B$4.3B$4.0B$4.4B$4.5B
YoY %+129.9%-46.3%-8.9%+11.6%+2.1%
Net Margin50.2%35.6%30.1%31.1%31.4%
EPS (GAAP)$71.97$38.22$34.77$38.34$41.48
YoY %+135.8%-46.9%-9.0%+10.3%+8.2%